SCHEMBL24070271

SCHEMBL24070271

O=C(O)c1c(Cl)cc(Cl)nc1N1CCS(=O)(=O)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
FABP3 P05413 3/20 0.39
FABP4 P15090 3/20 0.39
FABP5 Q01469 3/20 0.39
CYP2C9 P11712 2/20 0.39
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
ALDH1A1 P00352 3/20 0.35
APEX1 P27695 1/20 0.35
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CNR2 P34972 2/20 0.33
CNR1 P21554 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ATR Q13535 1/20 0.33
ATRIP Q8WXE1 1/20 0.33
FAAH O00519 1/20 0.32
LMNA P02545 1/20 0.32
AKT1 P31749 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25698017 0.85 FABP3 (0.50) FABP3FABP4FABP5CYP2C9CYP3A4
SCHEMBL25697994 0.81 NPSR1 (0.45) KDM4EFABP3FABP4FABP5CYP2C9
SCHEMBL24070539 0.78 SPR (0.44) FABP3FABP4FABP5CYP2C9CYP3A4
SCHEMBL23455371 0.77 KDM4E (0.54) KDM4EALDH1A1APEX1FAAHLMNA
SCHEMBL24070798 0.76 L3MBTL3 (0.38) FABP3FABP4FABP5CYP2C9CYP3A4
SCHEMBL25698228 0.76 SPR (0.46) FABP3FABP4FABP5CYP2C9ALDH1A1
SCHEMBL24070559 0.75 SPR (0.41) FABP3FABP4FABP5CYP2C9CYP3A4
SCHEMBL24069564 0.73 SPR (0.46) FABP3FABP4FABP5CYP2C9CYP3A4
SCHEMBL24069733 0.71 PIK3CA (0.37) NAMPT
SCHEMBL24069432 0.71 AKT1 (0.40) MAPK1AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-06-29 US disclosed
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-06-29 US disclosed
WO-2021239058-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 劲方医药科技(上海)有限公司 2021-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF KRAS, NRAS, TP53 KDM4E 4302/4885FABP3 4864/4885FABP4 4823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.